Eprotirome
As of the edition of 20 October 2026, Eprotirome is a small molecule: stopped in 2014; acts on THRB.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2014
- Kind
- Small molecule
- Registered trials
- 4, 1 stopped early
- Disease areas
- Nutrition and metabolism; Hormones; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Eprotirome.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| THRB | Thyroid hormone receptor beta | P10828 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 3 | 3 | 0 | 0 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Karo Bio | Lead sponsor of trials | 2006 to now |